Global Atropine Market Insights Forecasts to 2033

• The Global Atropine Market Size Was Estimated at USD 221.11 Million in 2023
• The Market Size is Expected to Grow at a CAGR of around 2.39% from 2023 to 2033
• The Worldwide Atropine Market Size is Expected to Reach USD 279.99 Million by 2033
• Asia Pacific is predicted to grow at the fastest CAGR throughout the projection period

The Global Atropine Market Size is Anticipated to Exceed USD 279.99 Million by 2033, Growing at a CAGR of 2.39% from 2023 to 2033. The market growth is propelled by extensive use in several medical treatments including bradycardia (slow heart rate), mushroom poisoning, and management of amblyopia along with the growing number of clinical trials.

Market Overview

The atropine market comprises the development, production, and sale of atropine, a pharmaceutical compound used in various therapeutic applications including pupil dilation, symptomatic bradycardia, and anticholinergic poisoning. Atropine, a racemic mixture of d- and l-hyoscyamine, is a sulfate salt and can be administered intravenously, subcutaneously, orally, etc. Oral atropine is only available in combination products.

The growing incidence of myopia is escalating the demand for atropine. For example, myopia, short-sightedness, or near-sightedness, is increasing globally in children, with 2.6 billion people affected in 2020. The World Health Organization anticipated raising the prevalence of myopia to 3.4 billion by 2030. The most commonly marketed product of atropine for the treatment of myopia in children is Myopine, an eyedrop containing 0.01% w/v atropine sulfate.

The global prevalence of bradycardia ranges from 0.5% to 2.0% in the general population leading to the rising need for atropine and its formulations for the management of bradycardia in society. For instance, A clinical study published in the American Journal of Medicine revealed that Atropine is the first-line treatment for symptomatic bradycardia that lowers the heart rate and alleviates symptoms.

The rising development and approvals of atropine and its derivatives by the regulatory authorities resulted in an increasing demand for atropine. For instance, the Food and Drug Administration (FDA) approved the Atropine Autoinjector, a crucial countermeasure against chemical nerve agents. The FDA and the Department of Defense (DoD) worked collaboratively concerning safety and efficacy requirements.

Report Coverage

This research report categorizes the global atropine market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global atropine market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global atropine market.

Driving Factors

Rising incidence of cardiovascular diseases:

Cardiovascular diseases are the leading cause of global mortality, with 80% of the 20.5 million deaths in 2021 occurring in low- and middle-income countries. Atropine, a WHO Essential Medicine, is a non-selective muscarinic receptor inhibitor used to treat acute sinus node dysfunction, bradycardia, and complete atrioventricular block, making it widely used in resuscitation and emergency cardiovascular care. Hence, increasing the prevalence of cardiovascular diseases resulting in the growth of the atropine market.

Proliferation of consumption of anesthesia and surgeries:

The epidemiological study published in the global population of 9 billion would require 321-5 million surgical procedures with rates varying across regions and subcategories of disease, ranging from nutritional deficiencies to unintentional injuries. Atropine's crucial role in anesthesia and emergency care drives market growth. It manages side effects and treats emergency conditions like bradycardia. The increasing frequency and complexity of surgeries enhance its market potential. Therefore, the extensive usage of anesthesia and the rising need for surgeries expand the market growth.

Restraining Factors

Atropine's market growth is hindered by potential side effects like dry mouth, blurred vision, constipation, and tachycardia, which may deter its use in routine medical treatments.

Market Segmentation

The global Atropine market share is classified into formulation, indication, and end-user

• The injectable segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR during the projected timeframe.

Based on the formulation, the global atropine market is categorized into injectables, oral, and ophthalmic. Among these, the injectable segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR during the projected timeframe. The segmental expansion is attributed to 100% bioavailability as it directly reaches into the systemic circulation without first-pass metabolism, rapid therapeutic effect, sustained drug delivery, uniform absorption of the drug, precise dosing, and effective in emergencies of patients suffering from life-threatening conditions.

• The ophthalmology segment accounted to grow at the fastest pace in 2023.

Based on the indication, the global atropine market is categorized into gastroenterology, poisoning treatment, respiratory medicine, ophthalmology, cardiology, anesthesia, and others. Among these, the ophthalmology segment accounted to grow at the fastest pace in 2023. The sector's dominance is owing to ongoing clinical trials and research and development activities. The growing prevalence of eye disorders like myopia worldwide and the usage of atropine in diagnostic procedures like cycloplegia propel the ophthalmology segment to the leading position in the market.

• The hospitals segment dominated the global atropine market in 2023 and is predicted to grow at a substantial CAGR throughout the projected timeframe.

Based on the end-user, the global atropine market is categorized as clinics, hospitals, ambulatory surgical centers, and retail pharmacies. Among these, the hospitals segment dominated the global atropine market in 2023 and is predicted to grow at a substantial CAGR throughout the projected timeframe. The segment growth is ascribed to provisions of advanced services, personalized treatment, frequent visits of doctors, and facilities of the intensive care units (ICU) for emergency patients.

Regional Segment Analysis of the Global Atropine Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global atropine market over the predicted timeframe.

North America is anticipated to hold the largest share of the global atropine market over the forecast period. North America's atropine market is driven by advanced healthcare infrastructure, research investment, and a robust regulatory framework, chronic diseases, and aging populations, effective therapeutic solutions, leading pharmaceutical companies, and public awareness support continuous development. The market's dominant position is expected to persist due to continuous innovations, increasing healthcare expenditures, and growth in personalized medicine and biotechnology.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. This is owing to rapid healthcare sector expansion, increased private and government investments, and high demand for better access to services. Technological advancements, such as digital medical records and telemedicine, are additionally contributing to market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global atropine market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Abbott Laboratories
• Syndnexis
• Amegen Inc
• Bayer AG
• Zoetis Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• AdvaCare Pharma
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In February 2024, Santen Pharmaceutical Co Ltd. announced that it had applied for manufacturing and marketing approval in Japan for the product STN1012700/DE-127 (generic name: atropine sulfate hydrate ophthalmic solution. DE-127 is an eyedrop treatment developed by Santen and the Singapore Eye Research Institute to slow myopia progression, containing 0.025% atropine sulfate hydrate.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global atropine market based on the below-mentioned segments:

Global Atropine Market, By Formulation

• Injectables
• Oral
• Ophthalmic

Global Atropine Market, By Indications

• Gastroenterology
• Poisoning treatment
• Respiratory Medicine
• Ophthalmology
• Cardiology
• Anesthesia
• Others

Global Atropine Market, By End-User

• Clinics
• Hospitals
• Ambulatory Surgical Centers
• Retail Pharmacies

Global Atropine Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East and Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East and Africa